Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q3 2024 Earnings Call Transcript
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q3 2024 Earnings Call Transcript October 31, 2024Alnylam Pharmaceuticals, Inc. beats earnings expectations.
Alnylam Pharmaceuticals Inc. (ALNY)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Orbis Investment Management William B. Gray | 1,268,112 | $348,768,844 | +76% | 1.84% |
| 2. | AQR Capital Management Cliff Asness | 505,654 | $138,953,719 | +87% | 0.19% |
| 3. | 100,000,000 | $117,092,300 | 1.74% | ||
| 4. | 80,000,000 | $93,720,000 | 3.27% | ||
| 5. | D E Shaw D. E. Shaw | 332,305 | $91,393,844 | +19% | 0.07% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $71.87 | 297,501 | Large Shareholder | 10,554,134 | 2017-05-31 | Filing | |
| $65.35 | 11,500 | Officer | 11,500 | 2017-05-30 | Filing | |
| $37.00 | 27,900 | Director | 27,900 | 2016-10-13 | Filing | |
| $58.36 | 2,000 | Director | 4,000 | 2016-03-09 | Filing | |
| $69.75 | 205,030 | Large Shareholder | 10,256,633 | 2016-02-01 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $280.00 | 15,000 | Officer, Director | 73,441 | 2024-08-20 | Filing | |
| $274.65 | 135 | Officer | 12,881 | 2024-08-12 | Filing | |
| $273.73 | 1,158 | Officer | 13,016 | 2024-08-12 | Filing | |
| $272.43 | 3,913 | Officer | 14,174 | 2024-08-12 | Filing | |
| $271.32 | 5,736 | Officer | 18,087 | 2024-08-12 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 16,174,563 | $3,096,023,554 | 0.55% | |
| 2. | 11,943,895 | $2,286,180,943 | 0.05% | |
| 3. | 10,312,356 | $1,973,888,016 | 0.15% | |
| 4. | 8,521,115 | $1,631,026,620 | 0.04% | |
| 5. | 7,214,198 | $1,380,869,641 | 0.25% |
News See All
Not Holding Alnylam Pharmaceuticals (ALNY) Hurt Fidelity Growth Strategies Fund’s Performance
Fidelity Investments, an investment management company, released its “Fidelity Growth Strategies Fund” second quarter 2024 investor letter. A copy of the letter can be downloaded here.
10 Best Aggressive Growth Stocks to Buy According to Hedge Funds
If you're putting money in the stock market, it's more likely than not that growth is the thing that's on your mind.
Here’s Why Alnylam Pharmaceuticals (ALNY) Surged in Q2
Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Mid Cap Growth Fund” second quarter 2024 investor letter. A copy of the letter can be downloaded here.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q2 2024 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to the Alnylam Pharmaceuticals Second Quarter 2024 Conference Call. At this time, all participants are in a listen-only mode.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q1 2024 Earnings Call Transcript
Alnylam Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.52272, expectations were $-0.75.
5 Most Promising Stocks to Buy Before They Take Off
In this article, we discuss the 5 most promising stocks to buy before they take off.
30 Biggest Biotechnology Companies in the World
In this article, we will be taking a look at the 30 biggest biotechnology companies in the world.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q4 2023 Earnings Call Transcript
Alnylam Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-1.1, expectations were $-1.2.
Billionaire Hedge Funds
